-TYRA will also present two posters on PK/PD
of TYRA-300 and a Trials-in-Progress from SURF301 -
CARLSBAD, Calif., Oct. 11,
2024 /PRNewswire/ -- Tyra Biosciences, Inc.
(Nasdaq: TYRA), a clinical-stage biotechnology company focused on
developing next-generation precision medicines that target large
opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
today announced the selection of three abstracts for presentation,
including a late-breaking oral presentation, at the 36th
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics (ENA 2024), taking place October 23-25, 2024, in Barcelona, Spain.
Details of the presentations are below:
Title: "Preliminary safety and anti-tumor activity of
TYRA-300, a highly selective FGFR3 inhibitor, in participants with
advanced solid tumors with activating FGFR3 mutations/fusions
(SURF301)"
Session: Late Breaking Abstracts and Proffered Papers: Novel
discoveries in drug development
Date: Friday, October 25, 2024
Time: 15:36 - 15:48 hrs CEST
Abstract #: LBA500
Title: "TYRA-300, an oral, FGFR3-selective inhibitor:
Preliminary pharmacokinetic and pharmacodynamic analysis from
SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in
advanced urothelial carcinoma and other solid tumors with
activating FGFR3 alterations"
Abstract #: 72
Poster #: PB060
Title: "A Multicenter, Open-label Phase 1/2 Study of TYRA 300
in Advanced Urothelial Carcinoma and Other Solid Tumors with
Activating FGFR3 Gene Alterations (SURF301)"
Abstract #: 35
Poster #: PB023
The abstracts related to the presentations are under embargo
until 00.01 hrs CEST on Friday, October 25,
2024.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage
biotechnology company focused on developing next-generation
precision medicines that target large opportunities in FGFR
biology. The Company's in-house precision medicine platform, SNÅP,
enables rapid and precise drug design through iterative molecular
SNÅPshots that help predict genetic alterations most likely to
cause acquired resistance to existing therapies. TYRA's initial
focus is on applying its accelerated small molecule drug discovery
engine to develop therapies in targeted oncology and genetically
defined conditions. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people,
please visit www.tyra.bio and engage with us on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-late-breaking-oral-presentation-on-preliminary-safety-and-anti-tumor-activity-of-tyra-300-from-surf301-at-the-36th-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics-ena-2024-302273982.html
SOURCE Tyra Biosciences